Venlafaxine

Overview

Venlafaxine, sold under the brand name Effexor among others, is an antidepressant medication of the serotonin–norepinephrine reuptake inhibitor (SNRI) class. It is used to treat major depressive disorder, generalized anxiety disorder, panic disorder, and social anxiety disorder. Studies have shown that venlafaxine improves post-traumatic stress disorder (PTSD) as a recommended first-line treatment. It may also be used for chronic neuropathic pain. It is taken orally (swallowed by mouth). It is also available as the salt venlafaxine besylate (venlafaxine benzenesulfonate monohydrate) in an extended-release formulation (Venbysi XR).[1–5] WP

Common side effects include loss of appetite, constipation, dry mouth, dizziness, sweating, insomnia, drowsiness and sexual problems. In some patients, sexual dysfunction may persist even after the drug is discontinued, a condition known as post-SSRI sexual dysfunction. Severe side effects include an increased risk of suicide, mania, and serotonin syndrome. Antidepressant withdrawal syndrome may occur if stopped. A meta-analysis of randomized trials in depression found an increased rate of serious adverse events, particularly sexual dysfunction and anorexia, and several non-serious adverse effects, including nervousness, asthenia, and tremor. There are concerns that use during the later part of pregnancy can harm the baby. Venlafaxine's mechanism of action is not entirely clear, but it seems to be related to the potentiation of the activity of some neurotransmitters in the brain.[2][6][7] WP

Venlafaxine was approved for medical use in the United States in 1993. It is available as a generic medication. In 2023, it was the 51st most commonly prescribed medication in the United States, with more than 13 million prescriptions.[2][8][9] WP

Drug class

Serotonin–norepinephrine reuptake inhibitor WP

From the Wikipedia article's infobox.

Uses, dosage and effects

Medical uses

Venlafaxine is used primarily for the treatment of depression, general anxiety disorder, social phobia, panic disorder, and vasomotor symptoms.[2] WP

Concerns that noradrenergic reuptake might precipitate anxiety have not been borne out in randomized trials: a 2016 systematic review of 52 double-blind, placebo-controlled studies (mostly with venlafaxine or duloxetine) found clinically significant improvements in anxiety symptoms and no signal for treatment-emergent anxiety attributable to SNRIs.[10] WP

Venlafaxine has been used off label for the treatment of diabetic neuropathy and migraine prevention. It may work on pain via effects on the opioid receptor. It has also been found to reduce the severity of 'hot flashes' in menopausal women and men on hormonal therapy for the treatment of prostate cancer.[11–15] WP

Due to its action on both the serotonergic and adrenergic systems, venlafaxine is also used as a treatment to reduce episodes of cataplexy, a form of muscle weakness, in patients with the sleep disorder narcolepsy. Some open-label and three double-blind studies have suggested the efficacy of venlafaxine in the treatment of attention deficit-hyperactivity disorder (ADHD). Clinical trials have found possible efficacy in those with post-traumatic stress disorder (PTSD). Case reports, open trials and blinded comparisons with established medications have suggested the efficacy of venlafaxine in the treatment of obsessive–compulsive disorder.[16–19] WP

Depression

A comparative meta-analysis of 21 major antidepressants found that venlafaxine, agomelatine, amitriptyline, escitalopram, mirtazapine, paroxetine, and vortioxetine were more effective than other antidepressants, although the quality of many comparisons was assessed as low or very low.[20][21] WP

Open-label evidence also suggests potential benefit in treatment-resistant cases: in a multicenter Canadian study of adults with inadequate response to prior antidepressants (n=159), 58% achieved response and 28% remission after 8 weeks of venlafaxine (mean 260 mg/day); tolerability was generally acceptable.[22] WP

Venlafaxine was similar in efficacy to the atypical antidepressant bupropion; however, the remission rate was lower for venlafaxine. In a double-blind study, patients who did not respond to an SSRI were switched to either venlafaxine or another SSRI (citalopram); similar improvement was observed in both groups.[23][24] WP

Studies have not established its efficacy for use in pediatric populations. In children and adolescents with depression, venlafaxine increases the risk of suicidal thoughts or attempts.[25–31] WP

Higher doses (e.g., 225 mg and 375 mg per day) of venlafaxine are more effective than lower doses (e.g., 75 mg per day) but also cause more side effects.[32] WP

Studies have shown that the extended-release is superior to the immediate-release form of venlafaxine.[33] WP

A 2017 meta-analysis has shown that the efficacy of venlafaxine is not correlated with baseline severity of depression. In other words, regardless of how severe a person's depression is at treatment initiation, the efficacy of venlafaxine remains consistent and is not influenced by the severity of depression at the start of treatment.[33] WP

Veterinary uses

Veterinary overdose in dogs is very well treated by cyproheptadine HCl.[34] WP

Venlafaxine is highly toxic to Bacillariophyta and Chlorophyta phytoplankton. Cats are drawn to the smell of venlafaxine and tend to ingest the pills, which are highly toxic to them.[35][36] WP

Risks and side effects

Contraindications

Venlafaxine is not recommended in patients hypersensitive to it, nor should it be taken by anyone who is allergic to the inactive ingredients, which include gelatin, cellulose, ethylcellulose, iron oxide, titanium dioxide and hypromellose. It should not be used in conjunction with a monoamine oxidase inhibitor (MAOI), as it can cause potentially fatal serotonin syndrome. Venlafaxine might interact with tramadol or other opioids, as well as trazodone and buspirone, so caution is needed while mixing multiple serotonergic agents together.[1][37][38][39] WP

Adverse effects

Venlafaxine can increase eye pressure, so those with glaucoma may require more frequent eye checks.[1] WP

A 2017 meta-analysis estimated venlafaxine discontinuation rate due to adverse effects to be 9.4%.[33] WP

Suicide

The US Food and Drug Administration (FDA) requires all antidepressants, including venlafaxine, to carry a black box warning with a generic warning about a possible suicide risk.[40] WP

A 2014 meta-analysis of 21 clinical trials of venlafaxine for the treatment of depression in adults found that compared to placebo, venlafaxine reduced the risk of suicidal thoughts and behavior.[41] WP

A study conducted in Finland followed more than 15,000 patients for 3.4 years. Venlafaxine increased suicide risk by 60% (statistically significant), as compared to no treatment. At the same time, fluoxetine (Prozac) halved the suicide risk.[42] WP

In a study sponsored by Wyeth, which produces and markets venlafaxine, the data on more than 200,000 cases were obtained from the UK general practice research database. At baseline, patients prescribed venlafaxine had a greater number of risk factors for suicide (such as prior suicide attempts) than patients treated with other anti-depressants. The patients taking venlafaxine had a significantly higher risk of suicide than the ones on fluoxetine or citalopram (Celexa). After adjusting for known risk factors, venlafaxine was associated with an increased risk of suicide relative to fluoxetine and dothiepin which was not statistically significant. A statistically significant greater risk for attempted suicide remained after adjustment, but the authors concluded that it could be due to residual confounding.[43] WP

An analysis of clinical trials by the FDA statisticians showed the incidence of suicidal behaviour among the adults on venlafaxine to be not significantly different from fluoxetine or placebo.[44] WP

Venlafaxine is contraindicated in children, adolescents, and young adults. In children and adolescents with depression, venlafaxine increases the risk of suicidal thoughts or attempts.[26–31] WP

Serotonin syndrome

The development of a potentially life-threatening serotonin syndrome (also classified as "serotonin toxicity") may occur with venlafaxine treatment, particularly with concomitant use of serotonergic drugs, including but not limited to SSRIs and SNRIs, many hallucinogens such as tryptamines and phenethylamines (e.g., LSD/LSA, DMT, MDMA, mescaline), dextromethorphan (DXM), tramadol, tapentadol, pethidine (meperidine) and triptans and with drugs that impair metabolism of serotonin (including MAOIs). Serotonin syndrome symptoms may include mental status changes (e.g. agitation, hallucinations, coma), autonomic instability (e.g. tachycardia, labile blood pressure, hyperthermia), neuromuscular aberrations (e.g. hyperreflexia, incoordination), or gastrointestinal symptoms (e.g. nausea, vomiting, diarrhea). Venlafaxine-induced serotonin syndrome has also been reported when venlafaxine has been taken in isolation in overdose. An abortive serotonin syndrome state, in which some but not all of the symptoms of the full serotonin syndrome are present, has been reported with venlafaxine at mid-range dosages (150 mg per day). A case of a patient with serotonin syndrome induced by low-dose venlafaxine (37.5 mg per day) has also been reported.[45–48] WP⚠ Wikipedia itself has flagged this text: citation needed.

Miscarriage

There are few well-controlled studies of venlafaxine in pregnant women. A study released in May 2010 by the Canadian Medical Association Journal suggests use of venlafaxine doubles the risk of miscarriage. A large case-control study done as part of the National Birth Defects Prevention Study and published in 2012 found a significant association between venlafaxine use during pregnancy and several birth defects including anencephaly, cleft palate, septal heart defects and coarctation of the aorta. Prospective studies have not shown any statistically significant congenital malformations. There have, however, been some reports of self-limiting effects on newborn infants. As with other serotonin reuptake inhibitors (SRIs), these effects are generally short-lived, lasting only 3 to 5 days, and rarely resulting in severe complications. According to the NHS, there is "no good evidence that taking venlafaxine in early pregnancy will affect your baby’s development", while also stating that a rare side effect is increased bleeding during childbirth.[49–56] WP

Bipolar disorder

According to the ISBD Task Force report on antidepressant use in bipolar disorder, during the course of treatment for depression with those suffering from bipolar I and II, venlafaxine "appears to carry a particularly high risk of inducing pathologically elevated states of mood and behavior." Because venlafaxine appears to be more likely than SSRIs and bupropion to induce mania and mixed episodes in these patients, provider discretion is advised through "carefully evaluating individual clinical cases and circumstances."[57] WP

Liver injury

A rare but serious side effect of venlafaxine is liver injury. It appears to affect both male and female patients with a median age of 44. Cessation of venlafaxine is one of the appropriate measures of management. While the mechanism of venlafaxine-related liver injury remains unclear, findings suggest that it may be related to a CYP2D6 polymorphism.[58] WP

Overdose

Most patients overdosing with venlafaxine develop only mild symptoms. Plasma venlafaxine concentrations in overdose survivors have ranged from 6 to 24 mg/L, while postmortem blood levels in fatalities are often in the 10–90 mg/L range. Published retrospective studies report that venlafaxine overdosage may be associated with an increased risk of fatal outcome compared to that observed with SSRI antidepressant products, but lower than that for tricyclic antidepressants. Healthcare professionals are advised to prescribe Effexor and Effexor XR in the smallest quantity of capsules consistent with good patient management to reduce the risk of overdose. It is usually reserved as a second-line treatment for depression due to a combination of its superior efficacy to the first-line treatments like fluoxetine, paroxetine and citalopram and greater frequency of side effects like nausea, headache, insomnia, drowsiness, dry mouth, constipation, sexual dysfunction, sweating and nervousness.[20][59][60][61] WP

There is no specific antidote for venlafaxine, and management is generally supportive, providing treatment for the immediate symptoms. Administration of activated charcoal can prevent absorption of the drug. Monitoring of cardiac rhythm and vital signs is indicated. Seizures are managed with benzodiazepines or other anticonvulsants. Forced diuresis, hemodialysis, exchange transfusion, or hemoperfusion are unlikely to be of benefit in hastening the removal of venlafaxine, due to the drug's high volume of distribution.[62] WP

Withdrawal syndrome

People stopping venlafaxine commonly experience SSRI withdrawal symptoms such as dysphoria, headaches, nausea, irritability, emotional lability, sensation of electric shocks (commonly called "brain zaps"), and sleep disturbance. Venlafaxine has a higher rate of moderate to severe withdrawal symptoms relative to other antidepressants (similar to the SSRI paroxetine).[63–66] WP

The higher risk and increased severity of withdrawal symptoms relative to other antidepressants may be related to the short half-life of venlafaxine and its active metabolite. After stopping venlafaxine, the levels of both serotonin and norepinephrine decrease, leading to the hypothesis that the withdrawal symptoms could result from an overly rapid reduction of neurotransmitter levels.[67][68] WP

Post-SSRI sexual dysfunction

Post-SSRI sexual dysfunction (PSSD) is an iatrogenic condition in which sexual side effects persist after discontinuation of serotonin reuptake inhibiting antidepressants, including venlafaxine. Characteristic symptoms include genital numbness, pleasureless or weak orgasm, loss of libido, and erectile dysfunction; non-sexual symptoms such as emotional blunting and cognitive impairment may also occur. The condition can arise after even brief exposure to a serotonin reuptake inhibitor and may persist indefinitely; there is currently no established treatment. A case study published in 2023 specifically documented PSSD symptoms—including low libido, delayed ejaculation, and erectile dysfunction—developing after discontinuation of venlafaxine, with 5-HT1A receptor downregulation proposed as a possible mechanism.[6][69][70][71] WP

A 2023 retrospective cohort study of over 12,000 males estimated the risk of irreversible sexual dysfunction (as measured by persistent need for phosphodiesterase inhibitors after antidepressant cessation) at approximately 0.46% of patients treated with serotonergic antidepressants, including SNRIs. The DSM-5 noted in 2013 that serotonin reuptake inhibitor–induced sexual dysfunction may persist after the agent is discontinued.[72][73] WP

In 2019, the European Medicines Agency's Pharmacovigilance Risk Assessment Committee recommended that product labels for all SSRIs and SNRIs, including venlafaxine, be updated to warn that sexual dysfunction may be long-lasting after treatment is stopped. Health Canada followed with similar label updates in 2021, and Australia's Therapeutic Goods Administration aligned all SSRI and SNRI product information in 2024, noting that venlafaxine already carried a warning about persistent sexual dysfunction.[74][75] WP

Other

In rare cases, drug-induced akathisia can occur after use in some people.[76] WP

Venlafaxine should be used with caution in hypertensive patients. Venlafaxine must be discontinued if significant hypertension persists. It can also have undesirable cardiovascular effects.[77–80] WP

Interactions

Interactions

Venlafaxine should be taken with caution when using St John's wort. Venlafaxine may lower the seizure threshold, and coadministration with other drugs that lower the seizure threshold such as bupropion and tramadol should be done with caution and at low doses.[81][82] WP

Pharmacology

Pharmacodynamics

Venlafaxine is usually categorized as a serotonin-norepinephrine reuptake inhibitor (SNRI), but it has also been referred to as a serotonin-norepinephrine-dopamine reuptake inhibitor (SNDRI). It is described as 'synthetic phenethylamine bicyclic derivative with antidepressant activity'. It works by blocking the transporter "reuptake" proteins for key neurotransmitters affecting mood, thereby leaving more active neurotransmitters in the synapse. The neurotransmitters affected are serotonin and norepinephrine. Additionally, in high doses, it weakly inhibits the reuptake of dopamine. The frontal cortex largely lacks dopamine transporters and instead relies on norepinephrine transporters for dopamine reuptake; therefore venlafaxine can increase dopamine neurotransmission in this part of the brain.[12][83–88] WP

Venlafaxine selectively inhibits the serotonin transporter at lower doses, but at a dose of 225 mg per day it additionally blocks the norepinephrine transporter (NET), as measured by the intravenous tyramine pressor test.[89] WP

Venlafaxine indirectly affects opioid receptors as well as the α₂-adrenergic receptor, and was shown to increase pain threshold in mice. These benefits with respect to pain were reversed with naloxone, an opioid antagonist, thus supporting an opioid mechanism.[13][90] WP

Pharmacokinetics

Venlafaxine is well absorbed, with at least 92% of an oral dose being absorbed into systemic circulation. It is extensively metabolized in the liver via the CYP2D6 isoenzyme to desvenlafaxine (O-desmethylvenlafaxine, now marketed as a separate medication named Pristiq), which is just as potent an SNRI as the parent compound, meaning that the differences in metabolism between extensive and poor metabolisers are not clinically important in terms of efficacy. Side effects, however, are reported to be more severe in CYP2D6 poor metabolisers. Steady-state concentrations of venlafaxine and its metabolite are attained in the blood within 3 days. Therapeutic effects are usually achieved within 3 to 4 weeks. No accumulation of venlafaxine has been observed during chronic administration in healthy subjects. The primary route of excretion of venlafaxine and its metabolites is via the kidneys. The half-life of venlafaxine is relatively short, so patients are directed to adhere to a strict medication routine, avoiding missing a dose. Even a single missed dose can result in withdrawal symptoms.[1][91–94] WP

Venlafaxine is a substrate of P-glycoprotein (P-gp), which pumps it out of the brain. The gene encoding P-gp, ABCB1, has the SNP rs2032583, with alleles C and T. The majority of people (about 70% of Europeans and 90% of East Asians) have the TT variant. A 2007 study found that carriers of at least one C allele (variant CC or CT) are 7.72 times more likely than non-carriers to achieve remission after 4 weeks of treatment with amitriptyline, citalopram, paroxetine or venlafaxine (all P-gp substrates). The study included patients with mood disorders other than major depression, such as bipolar II; the ratio is 9.4 if these other disorders are excluded. At the 6-week mark, 75% of C-carriers had remitted, compared to only 38% of non-carriers.[95][96] WP⚠ Part of this sentence could not be copied from the source. Open the source to read it in full.⚠ Wikipedia itself has flagged this text: citation needed.

Legal status

Brand names

Venlafaxine was originally marketed as Effexor in most of the world; generic venlafaxine has been available since around 2008 and extended-release venlafaxine has been available since around 2010.[97] WP

Venlafaxine is sold under many brand names worldwide. In some countries, Effexor is marketed by Viatris after Upjohn was spun off from Pfizer.[98][99][100] WP

Chemistry

Formula

C17H27NO2 PC

CAS number

93413-69-5 PC

Molar mass (g/mol)

277.4 PC

IUPAC name (computed by PubChem)

1-[2-(dimethylamino)-1-(4-methoxyphenyl)ethyl]cyclohexan-1-ol PC

SMILES

CN(C)CC(C1=CC=C(C=C1)OC)C2(CCCCC2)O PC

InChIKey

PNVNVHUZROJLTJ-UHFFFAOYSA-N PC

PubChem CID

5656

Harm reduction information

No harm reduction data is on file for this compound yet. That means no dose, timing or combination data from PsychonautWiki or TripSit. Please don't guess a dose from similar compounds. If you have taken it and feel unwell, contact emergency services or a poison control center.

User reports

Pop culture

No references added yet.

Sources

1. Journal / agency Effexor XR- venlafaxine hydrochloride capsule, extended release
2. Other Venlafaxine Hydrochloride Monograph for Professionals
3. Journal / agency Forman-Hoffman V, Middleton JC, Feltner C, Gaynes BN, Weber RP, Bann C, Viswanathan M, Lohr KN, Baker C, Green J. Psychological and Pharmacological Treatments for Adults With Posttraumatic Stress Disorder: A Systematic Review Update. 17 May 2018. doi:10.23970/ahrqepccer207 · PMID 30204376
4. Other Antidepressants: Another weapon against chronic pain
5. Journal / agency Venlafaxine tablet, extended release. 30 June 2022
6. Journal / agency Healy D, Bahrick A, Bak M, Barbato A, Calabro RS, Chubak BM, Cosci F, Csoka AB, D'Avanzo B, Diviccaro S, Giatti S, Goldstein I, Graf H, Hellstrom WJ, Irwig MS, Jannini EA, Janssen PK, Khera M, Kumar MT, Le Noury J, Lew-Starowicz M, Linden DE, Lüning C, Mangin D, Melcangi RC, Muquebil Ali Al Shaban Rodríguez OW, Panicker JN, Patacchini A, Pearlman AM, Pukall CF, Raj S, Reisman Y, Rubin RS, Schreiber R, Shipko S, Vašečková B, Waraich A. Diagnostic criteria for enduring sexual dysfunction after treatment with antidepressants, finasteride and isotretinoin. International Journal of Risk & Safety in Medicine. 2022. doi:10.3233/JRS-210023 · PMID 34719438 · PMC8925105
7. Journal / agency Kamp CB, Petersen JJ, Faltermeier P, Juul S, Siddiqui F, Moncrieff J, Horowitz MA, Hengartner MP, Kirsch I, Gluud C, Jakobsen JC. The risks of adverse events with venlafaxine for adults with major depressive disorder: a systematic review of randomised clinical trials with meta-analysis and Trial Sequential Analysis. Epidemiology and Psychiatric Sciences. October 2024. doi:10.1017/S2045796024000520 · PMID 39440379 · PMC11561525
8. Other Top 300 of 2023
9. Other Venlafaxine Drug Usage Statistics, United States, 2014 - 2022
10. Journal / agency Montoya A, Bruins R, Katzman MA, Blier P. The noradrenergic paradox: implications in the management of depression and anxiety. Neuropsychiatric Disease and Treatment. 2016. doi:10.2147/NDT.S91311 · PMID 27042068 · PMC4780187
11. Journal / agency Grothe DR, Scheckner B, Albano D. Treatment of pain syndromes with venlafaxine. Pharmacotherapy. May 2004. doi:10.1592/phco.24.6.621.34748 · PMID 15162896
12. Journal / agency Singh D, Saadabadi A. StatPearls. 2022. PMID 30570984
13. Other The Opioid System as the Interface between the Brain's Cognitive and Motivational Systems. 2018
14. Other Mayo Clinic staff. Beyond hormone therapy: Other medicines may help. 2005
15. Journal / agency Schober CE, Ansani NT. Venlafaxine hydrochloride for the treatment of hot flashes. The Annals of Pharmacotherapy. November 2003. doi:10.1345/aph.1C483 · PMID 14565812
16. Other Medications. 7 February 2003
17. Journal / agency Ghanizadeh A, Freeman RD, Berk M. Efficacy and adverse effects of venlafaxine in children and adolescents with ADHD: a systematic review of non-controlled and controlled trials. Reviews on Recent Clinical Trials. March 2013. doi:10.2174/1574887111308010002 · PMID 23157376
18. Journal / agency Pae CU, Lim HK, Ajwani N, Lee C, Patkar AA. Extended-release formulation of venlafaxine in the treatment of post-traumatic stress disorder. Expert Review of Neurotherapeutics. June 2007. doi:10.1586/14737175.7.6.603 · PMID 17563244
19. Journal / agency Phelps NJ, Cates ME. The role of venlafaxine in the treatment of obsessive-compulsive disorder. The Annals of Pharmacotherapy. January 2005. doi:10.1345/aph.1E362 · PMID 15585743
20. Journal / agency Cipriani A, Furukawa TA, Salanti G, Geddes JR, Higgins JP, Churchill R, Watanabe N, Nakagawa A, Omori IM, McGuire H, Tansella M, Barbui C. Comparative efficacy and acceptability of 12 new-generation antidepressants: a multiple-treatments meta-analysis. Lancet. February 2009. doi:10.1016/S0140-6736(09)60046-5 · PMID 19185342
21. Journal / agency Cipriani A, Furukawa TA, Salanti G, Chaimani A, Atkinson LZ, Ogawa Y, Leucht S, Ruhe HG, Turner EH, Higgins JP, Egger M, Takeshima N, Hayasaka Y, Imai H, Shinohara K, Tajika A, Ioannidis JP, Geddes JR. Comparative efficacy and acceptability of 21 antidepressant drugs for the acute treatment of adults with major depressive disorder: a systematic review and network meta-analysis. Lancet. April 2018. doi:10.1016/S0140-6736(17)32802-7 · PMID 29477251 · PMC5889788
22. Journal / agency de Montigny C, Silverstone PH, Debonnel G, Blier P, Bakish D. Venlafaxine in treatment-resistant major depression: a Canadian multicenter, open-label trial. Journal of Clinical Psychopharmacology. 1999. doi:10.1097/00004714-199910000-00003 · PMID 10505581
23. Journal / agency Thase ME, Clayton AH, Haight BR, Thompson AH, Modell JG, Johnston JA. A double-blind comparison between bupropion XL and venlafaxine XR: sexual functioning, antidepressant efficacy, and tolerability. Journal of Clinical Psychopharmacology. October 2006. doi:10.1097/01.jcp.0000239790.83707.ab · PMID 16974189
24. Journal / agency Lenox-Smith AJ, Jiang Q. Venlafaxine extended release versus citalopram in patients with depression unresponsive to a selective serotonin reuptake inhibitor. International Clinical Psychopharmacology. May 2008. doi:10.1097/YIC.0b013e3282f424c2 · PMID 18408525
25. Journal / agency Courtney DB. Selective serotonin reuptake inhibitor and venlafaxine use in children and adolescents with major depressive disorder: a systematic review of published randomized controlled trials. Canadian Journal of Psychiatry. August 2004. doi:10.1177/070674370404900807 · PMID 15453105
26. Journal / agency Antidepressants for children and teenagers: what works for anxiety and depression?. NIHR Evidence. 3 November 2022. doi:10.3310/nihrevidence_53342
27. Journal / agency Zhou X, Teng T, Zhang Y, Del Giovane C, Furukawa TA, Weisz JR, Li X, Cuijpers P, Coghill D, Xiang Y, Hetrick SE, Leucht S, Qin M, Barth J, Ravindran AV, Yang L, Curry J, Fan L, Silva SG, Cipriani A, Xie P. Comparative efficacy and acceptability of antidepressants, psychotherapies, and their combination for acute treatment of children and adolescents with depressive disorder: a systematic review and network meta-analysis. The Lancet. Psychiatry. July 2020. doi:10.1016/S2215-0366(20)30137-1 · PMID 32563306 · PMC7303954
28. Journal / agency Hetrick SE, McKenzie JE, Bailey AP, Sharma V, Moller CI, Badcock PB, Cox GR, Merry SN, Meader N. New generation antidepressants for depression in children and adolescents: a network meta-analysis. The Cochrane Database of Systematic Reviews. May 2021. doi:10.1002/14651858.CD013674.pub2 · PMID 34029378 · PMC8143444
29. Journal / agency Solmi M, Fornaro M, Ostinelli EG, Zangani C, Croatto G, Monaco F, Krinitski D, Fusar-Poli P, Correll CU. Safety of 80 antidepressants, antipsychotics, anti-attention-deficit/hyperactivity medications and mood stabilizers in children and adolescents with psychiatric disorders: a large scale systematic meta-review of 78 adverse effects. World Psychiatry. June 2020. doi:10.1002/wps.20765 · PMID 32394557 · PMC7215080
30. Journal / agency Boaden K, Tomlinson A, Cortese S, Cipriani A. Antidepressants in Children and Adolescents: Meta-Review of Efficacy, Tolerability and Suicidality in Acute Treatment. Frontiers in Psychiatry. 2 September 2020. doi:10.3389/fpsyt.2020.00717 · PMID 32982805 · PMC7493620
31. Journal / agency Correll CU, Cortese S, Croatto G, Monaco F, Krinitski D, Arrondo G, Ostinelli EG, Zangani C, Fornaro M, Estradé A, Fusar-Poli P, Carvalho AF, Solmi M. Efficacy and acceptability of pharmacological, psychosocial, and brain stimulation interventions in children and adolescents with mental disorders: an umbrella review. World Psychiatry. June 2021. doi:10.1002/wps.20881 · PMID 34002501 · PMC8129843
32. Journal / agency Rudolph RL, Fabre LF, Feighner JP, Rickels K, Entsuah R, Derivan AT. A randomized, placebo-controlled, dose-response trial of venlafaxine hydrochloride in the treatment of major depression. The Journal of Clinical Psychiatry. March 1998. doi:10.4088/jcp.v59n0305 · PMID 9541154
33. Journal / agency Thase M, Asami Y, Wajsbrot D, Dorries K, Boucher M, Pappadopulos E. A meta-analysis of the efficacy of venlafaxine extended release 75-225 mg/day for the treatment of major depressive disorder. Current Medical Research and Opinion. February 2017. doi:10.1080/03007995.2016.1255185 · PMID 27794623
34. Other Veterinary Toxicology: Basic and Clinical Principles. 2012
35. Journal / agency Chia MA, Lorenzi AS, Ameh I, Dauda S, Cordeiro-Araújo MK, Agee JT, Okpanachi IY, Adesalu AT. Susceptibility of phytoplankton to the increasing presence of active pharmaceutical ingredients (APIs) in the aquatic environment: A review. Aquatic Toxicology. May 2021. doi:10.1016/j.aquatox.2021.105809 · PMID 33780670
36. Other The Top 5 Cat Toxins
37. Other Efexor-XR (venlafaxine hydrochloride)
38. Other The Maudsley Prescribing Guidelines in Psychiatry. 2012
39. Journal / agency Ripple MG, Pestaner JP, Levine BS, Smialek JE. Lethal combination of tramadol and multiple drugs affecting serotonin. The American Journal of Forensic Medicine and Pathology. December 2000. doi:10.1097/00000433-200012000-00015 · PMID 11111800
40. Journal / agency Spielmans GI, Spence-Sing T, Parry P. Duty to Warn: Antidepressant Black Box Suicidality Warning Is Empirically Justified. Frontiers in Psychiatry. 2020. doi:10.3389/fpsyt.2020.00018 · PMID 32116839 · PMC7031767
41. Journal / agency Gibbons RD, Brown CH, Hur K, Davis J, Mann JJ. Suicidal thoughts and behavior with antidepressant treatment: reanalysis of the randomized placebo-controlled studies of fluoxetine and venlafaxine. Archives of General Psychiatry. June 2012. doi:10.1001/archgenpsychiatry.2011.2048 · PMID 22309973 · PMC3367101
42. Journal / agency Tiihonen J, Lönnqvist J, Wahlbeck K, Klaukka T, Tanskanen A, Haukka J. Antidepressants and the risk of suicide, attempted suicide, and overall mortality in a nationwide cohort. Archives of General Psychiatry. December 2006. doi:10.1001/archpsyc.63.12.1358 · PMID 17146010
43. Journal / agency Rubino A, Roskell N, Tennis P, Mines D, Weich S, Andrews E. Risk of suicide during treatment with venlafaxine, citalopram, fluoxetine, and dothiepin: retrospective cohort study. BMJ. February 2007. doi:10.1136/bmj.39041.445104.BE · PMID 17164297 · PMC1790752
44. Journal / agency Overview for December 13 Meeting of Psychopharmacologic Drugs Advisory Committee. 16 November 2006
45. Journal / agency Dunkley EJ, Isbister GK, Sibbritt D, Dawson AH, Whyte IM. The Hunter Serotonin Toxicity Criteria: simple and accurate diagnostic decision rules for serotonin toxicity. QJM. September 2003. doi:10.1093/qjmed/hcg109 · PMID 12925718
46. Journal / agency Kolecki P. Isolated venlafaxine-induced serotonin syndrome. The Journal of Emergency Medicine. July–August 1997. doi:10.1016/S0736-4679(97)00078-4 · PMID 9279702
47. Other Ebert D, etal. Hallucinations as a side effect of venlafaxine treatment
48. Journal / agency Pan JJ, Shen WW. Serotonin syndrome induced by low-dose venlafaxine. The Annals of Pharmacotherapy. February 2003. doi:10.1345/aph.1C021 · PMID 12549949
49. Journal / agency Broy P, Bérard A. Gestational exposure to antidepressants and the risk of spontaneous abortion: a review. Current Drug Delivery. January 2010. doi:10.2174/156720110790396508 · PMID 19863482
50. Journal / agency Nakhai-Pour HR, Broy P, Bérard A. Use of antidepressants during pregnancy and the risk of spontaneous abortion. CMAJ. July 2010. doi:10.1503/cmaj.091208 · PMID 20513781 · PMC2900326
51. Journal / agency Polen KN, Rasmussen SA, Riehle-Colarusso T, Reefhuis J. Association between reported venlafaxine use in early pregnancy and birth defects, national birth defects prevention study, 1997-2007. Birth Defects Research. Part A, Clinical and Molecular Teratology. January 2013. doi:10.1002/bdra.23096 · PMID 23281074 · PMC4484721
52. Journal / agency Gentile S. The safety of newer antidepressants in pregnancy and breastfeeding. Drug Safety. 2005. doi:10.2165/00002018-200528020-00005 · PMID 15691224
53. Journal / agency de Moor RA, Mourad L, ter Haar J, Egberts AC. Withdrawal symptoms in a neonate following exposure to venlafaxine during pregnancy. Nederlands Tijdschrift voor Geneeskunde. July 2003. PMID 12892015
54. Journal / agency Ferreira E, Carceller AM, Agogué C, Martin BZ, St-André M, Francoeur D, Bérard A. Effects of selective serotonin reuptake inhibitors and venlafaxine during pregnancy in term and preterm neonates. Pediatrics. January 2007. doi:10.1542/peds.2006-2133 · PMID 17200271
55. Journal / agency Moses-Kolko EL, Bogen D, Perel J, Bregar A, Uhl K, Levin B, Wisner KL. Neonatal signs after late in utero exposure to serotonin reuptake inhibitors: literature review and implications for clinical applications. JAMA. May 2005. doi:10.1001/jama.293.19.2372 · PMID 15900008
56. Other Pregnancy, breastfeeding and fertility while taking venlafaxine
57. Journal / agency Pacchiarotti I, Bond DJ, Baldessarini RJ, Nolen WA, Grunze H, Licht RW, Post RM, Berk M, Goodwin GM, Sachs GS, Tondo L, Findling RL, Youngstrom EA, Tohen M, Undurraga J, González-Pinto A, Goldberg JF, Yildiz A, Altshuler LL, Calabrese JR, Mitchell PB, Thase ME, Koukopoulos A, Colom F, Frye MA, Malhi GS, Fountoulakis KN, Vázquez G, Perlis RH, Ketter TA, Cassidy F, Akiskal H, Azorin JM, Valentí M, Mazzei DH, Lafer B, Kato T, Mazzarini L, Martínez-Aran A, Parker G, Souery D, Ozerdem A, McElroy SL, Girardi P, Bauer M, Yatham LN, Zarate CA, Nierenberg AA, Birmaher B, Kanba S, El-Mallakh RS, Serretti A, Rihmer Z, Young AH, Kotzalidis GD, MacQueen GM, Bowden CL, Ghaemi SN, Lopez-Jaramillo C, Rybakowski J, Ha K, Perugi G, Kasper S, Amsterdam JD, Hirschfeld RM, Kapczinski F, Vieta E. The International Society for Bipolar Disorders (ISBD) task force report on antidepressant use in bipolar disorders. The American Journal of Psychiatry. November 2013. doi:10.1176/appi.ajp.2013.13020185 · PMID 24030475 · PMC4091043
58. Journal / agency Stadlmann S, Portmann S, Tschopp S, Terracciano LM. Venlafaxine-induced cholestatic hepatitis: case report and review of literature. The American Journal of Surgical Pathology. November 2012. doi:10.1097/pas.0b013e31826af296 · PMID 23073329
59. Other Baselt R. Disposition of Toxic Drugs and Chemicals in Man. 2008
60. Journal / agency Wyeth Letter to Health Care Providers. 2006
61. Journal / agency Taylor D, Lenox-Smith A, Bradley A. A review of the suitability of duloxetine and venlafaxine for use in patients with depression in primary care with a focus on cardiovascular safety, suicide and mortality due to antidepressant overdose. Therapeutic Advances in Psychopharmacology. June 2013. doi:10.1177/2045125312472890 · PMID 24167687 · PMC3805457
62. Journal / agency Hanekamp BB, Zijlstra JG, Tulleken JE, Ligtenberg JJ, van der Werf TS, Hofstra LS. Serotonin syndrome and rhabdomyolysis in venlafaxine poisoning: a case report. The Netherlands Journal of Medicine. September 2005. PMID 16186642
63. Journal / agency Papp A, Onton JA. Brain Zaps: An Underappreciated Symptom of Antidepressant Discontinuation. The Primary Care Companion for CNS Disorders. December 2018. doi:10.4088/PCC.18m02311 · PMID 30605268
64. Journal / agency Rizkalla M, Kowalkowski B, Prozialeck WC. Antidepressant Discontinuation Syndrome: A Common but Underappreciated Clinical Problem. The Journal of the American Osteopathic Association. February 2020. doi:10.7556/jaoa.2020.030 · PMID 32077900
65. Journal / agency Petit J, Sansone RA. A case of interdose discontinuation symptoms with venlafaxine extended release. The Primary Care Companion for CNS Disorders. 2011. doi:10.4088/PCC.11l01140 · PMID 22295261 · PMC3267502
66. Journal / agency Hosenbocus S, Chahal R. SSRIs and SNRIs: A review of the Discontinuation Syndrome in Children and Adolescents. Journal of the Canadian Academy of Child and Adolescent Psychiatry. February 2011. PMID 21286371 · PMC3024727
67. Journal / agency Haddad PM. Antidepressant discontinuation syndromes. Drug Safety. March 2001. doi:10.2165/00002018-200124030-00003 · PMID 11347722
68. Journal / agency Campagne DM. Venlafaxine and serious withdrawal symptoms: warning to drivers. MedGenMed. July 2005. PMID 16369248 · PMC1681629
69. Journal / agency Bala A, Tue Nguyen HM, Hellstrom WJ. Post-SSRI Sexual Dysfunction: A Literature Review. Sexual Medicine Reviews. January 2018. doi:10.1016/j.sxmr.2017.07.002 · PMID 28778697
70. Journal / agency Healy D, Le Noury J, Mangin D. Enduring sexual dysfunction after treatment with antidepressants, 5α-reductase inhibitors and isotretinoin: 300 cases. International Journal of Risk & Safety in Medicine. 2018. doi:10.3233/JRS-180744 · PMID 29733030 · PMC6004900
71. Journal / agency Klaas SJ, Pouwels S, Hajji N. The pathophysiology of Post SSRI Sexual Dysfunction – Lessons from a case study. Biomedicine & Pharmacotherapy. February 2023. doi:10.1016/j.biopha.2022.114165 · PMID 36898260
72. Journal / agency Ben-Sheetrit J, Aizenberg D, Csoka AB, Weizman A, Hermesh H. Estimating the risk of irreversible post-SSRI sexual dysfunction (PSSD) due to serotonergic antidepressants. Annals of General Psychiatry. April 2023. doi:10.1186/s12991-023-00447-0 · PMID 37076856 · PMC10122283
73. Journal / agency Healy D, Mangin D. Post-SSRI sexual dysfunction: barriers to quantifying incidence and prevalence. Epidemiology and Psychiatric Sciences. 2024. doi:10.1017/S2045796024000532 · PMID 39363727 · PMC11450419
74. Journal / agency PRAC recommendations on signals adopted at the 13–16 May 2019 PRAC meeting. 11 June 2019
75. Other Updated warnings about persistent sexual dysfunction for antidepressants. 23 May 2024
76. Other Venlafaxine Side Effects in Detail
77. Journal / agency Khurana RN, Baudendistel TE. Hypertensive crisis associated with venlafaxine. The American Journal of Medicine. December 2003. doi:10.1016/S0002-9343(03)00472-8 · PMID 14656626
78. Journal / agency Thase ME. Effects of venlafaxine on blood pressure: a meta-analysis of original data from 3744 depressed patients. The Journal of Clinical Psychiatry. October 1998. doi:10.4088/JCP.v59n1002 · PMID 9818630
79. Journal / agency Edvardsson B. Venlafaxine as single therapy associated with hypertensive encephalopathy. SpringerPlus. 26 February 2015. doi:10.1186/s40064-015-0883-0 · PMID 25763307 · PMC4348355
80. Journal / agency Johnson EM, Whyte E, Mulsant BH, Pollock BG, Weber E, Begley AE, Reynolds CF. Cardiovascular changes associated with venlafaxine in the treatment of late-life depression. The American Journal of Geriatric Psychiatry. September 2006. doi:10.1097/01.JGP.0000204328.50105.b3 · PMID 16943176
81. Other Karch A. 2006 Lippincott's Nursing Drug Guide. 2006
82. Journal / agency Thundiyil JG, Kearney TE, Olson KR. Evolving epidemiology of drug-induced seizures reported to a Poison Control Center System. Journal of Medical Toxicology. March 2007. doi:10.1007/BF03161033 · PMID 18072153 · PMC3550124
83. Other ClinicalTrialsGov NCT00001483 Acute Effectiveness of Additional Drugs to the Standard Treatment of Depression
84. Journal / agency Goeringer KE, McIntyre IM, Drummer OH. Postmortem tissue concentrations of venlafaxine. Forensic Science International. September 2001. doi:10.1016/S0379-0738(01)00455-8 · PMID 11516890
85. Other venlafaxine
86. Journal / agency Wellington K, Perry CM. Venlafaxine extended-release: a review of its use in the management of major depression. CNS Drugs. 2001. doi:10.2165/00023210-200115080-00007 · PMID 11524036
87. Other Stahl's Essential Psychopharmacology – Cambridge University Press
88. Journal / agency Delgado PL, Moreno FA. Role of norepinephrine in depression. The Journal of Clinical Psychiatry. 2000. PMID 10703757
89. Journal / agency Aldosary F, Norris S, Tremblay P, James JS, Ritchie JC, Blier P. Differential Potency of Venlafaxine, Paroxetine, and Atomoxetine to Inhibit Serotonin and Norepinephrine Reuptake in Patients With Major Depressive Disorder. The International Journal of Neuropsychopharmacology. April 2022. doi:10.1093/ijnp/pyab086 · PMID 34958348 · PMC9017767
90. Other Stern TA, Fava M, Wilens TE, Rosenbaum JF. Massachusetts General Hospital Comprehensive Clinical Psychiatry. 2015
91. Journal / agency Pae CU. Desvenlafaxine in the treatment of major depressive disorder. Expert Opinion on Pharmacotherapy. December 2011. doi:10.1517/14656566.2011.636033 · PMID 22098230
92. Journal / agency Shams ME, Arneth B, Hiemke C, Dragicevic A, Müller MJ, Kaiser R, Lackner K, Härtter S. CYP2D6 polymorphism and clinical effect of the antidepressant venlafaxine. Journal of Clinical Pharmacy and Therapeutics. October 2006. doi:10.1111/j.1365-2710.2006.00763.x · PMID 16958828
93. Journal / agency Dean L. Medical Genetics Summaries. 2015. PMID 28520361
94. Journal / agency Parker G, Blennerhassett J. Withdrawal reactions associated with venlafaxine. The Australian and New Zealand Journal of Psychiatry. April 1998. doi:10.3109/00048679809062742 · PMID 9588310
95. Other Rs2032583 -SNPedia
96. Journal / agency Uhr M, Tontsch A, Namendorf C, Ripke S, Lucae S, Ising M, Dose T, Ebinger M, Rosenhagen M, Kohli M, Kloiber S, Salyakina D, Bettecken T, Specht M, Pütz B, Binder EB, Müller-Myhsok B, Holsboer F. Polymorphisms in the drug transporter gene ABCB1 predict antidepressant treatment response in depression. Neuron. January 2008. doi:10.1016/j.neuron.2007.11.017 · PMID 18215618
97. Other Staton T. Drugstores accuse Pfizer, Teva of blocking Effexor generics. 13 June 2012
98. Other Venlafaxine (International). January 2020
99. Other Pfizer Completes Transaction to Combine Its Upjohn Business with Mylan. 16 November 2020
100. Other Brands. 16 November 2020

Text and values on this page are quoted from Wikipedia (CC BY-SA 4.0), PubChem (public domain). Each value links to the exact revision it came from.